Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa-2b Combined With Didanosine in Kaposi's Sarcoma
NCT00001114Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, randomised trial of interferon alfa-2b in Kaposi's sarcoma (KS) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Toxicity and Antitumor Activity. Status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
Kaposi's sarcoma (KS)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001114.